From: Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas
Univariate Analysis | ||||
---|---|---|---|---|
OS | PFS | |||
Characteristics | Median (mo) | p Valuesb | Median (mo) | p Valuesb |
Group | 0.751 | 0.203 | ||
SI | 22 (14.50–29.50) | 8 (5.47–10.53) | ||
SRCI | 21 (18.89–23.11) | 7 (4.74–9.26) | ||
Age | 0.006 | 0.029 | ||
≥ 60 | 22 (20.36–23.64) | 8 (6.81–9.19) | ||
< 60 | 17 (11.82–22.18) | 4 (2.06–5.94) | ||
KPS | < 0.001 | < 0.001 | ||
90–100 | 35 (23.63–46.38) | 12 (8.80–15.20) | ||
≤ 80 | 16 (14.17–17.84) | 6 (5.14–6.86) | ||
Tumor Position | 0.074 | |||
Frontal lobe | 10 (7.31–12.69) | |||
Occipital lobe | 13 | |||
Parietal lobe | 8 (0.00–28.58) | |||
Temporal lobe | 7 (4.30–9.70) | |||
multi-lobe | 6 (5.32–6.68) | |||
tumor diameter | 0.015 | |||
≥ 5 cm | 9 (6.99–11.01) | |||
< 5 cm | 6 (5.24–6.76) | |||
Vertigo | 0.074 | |||
NO | 8 (6.70–9.30) | |||
Yes | 5 (3.64–6.36) | |||
Nausea | 0.040 | |||
No | 9 (6.06–11.94) | |||
Yes | 6 (4.36–7.64) | |||
Vomit | 0.078 | |||
No | 8 (6.38–9.62) | |||
Yes | 6 (4.33–7.67) |